Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Head and Neck Neoplasms 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1

Interventions

cabozantinib 2Everolimus 2veliparib 1vatalanib 1temsirolimus 1sargramostim 1rovalpituzumab tesirine 1pentetreotide 1cixutumumab 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Salts 1Octreotide 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Dexamethasone 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × rovalpituzumab tesirine × Dermatologic × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡